Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M3258 in Relapsed Refractory Multiple Myeloma
NCT04075721Phase 1Terminated
- Sponsor
- EMD Serono
- Start
- Sep 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of m3258 in multiple myeloma (MM) (3 arms), sponsored by EMD Serono. Primary endpoints: Dose-Limiting Toxicities, Treatment-Emergent Adverse Events up to 24.3 weeks and 3 more. Started Sep 2019; status: terminated.
02
Drugs
m3258
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04075721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075721.